subscribeSubscribe

Top Pharma Companies & Drugs in 2022: Pfizer breaks US$ 100 bn barrier, AbbVie’s Humira retains 2nd spot

Excel Download
Top Pharma Companies & Drugs in 2022: Pfizer breaks US$ 100 bn barrier, AbbVie’s Humira retains 2nd spot
 

Impressions: 1840

In 2022, the pandemic continued to bring in a windfall for pharmaceutical companies manufacturing Covid-19 products, with Pfizer’s total annual sales reaching a record high by surpassing US$ 100 billion for the first time.AbbVie, despite not ...

https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-and-drugs-in-2022-pfizer-breaks-us-100-billion-barrier-abbvie-s-humira-retains-second-spot

#PharmaFlow by PHARMACOMPASS
01 Jun 2023
Share Share

Drop in Covid sales, trial failures, restructuring trigger steep rise in layoffs in Q1 2023

Excel Download
Drop in Covid sales, trial failures, restructuring trigger steep rise in layoffs in Q1 2023
 

Impressions: 1546

Since 2022, layoffs have become commonplace. The ongoing global banking crisis, coupled with pre-existing factors such as the Ukraine-Russia conflict, inflation, looming recession and rising interest rates have made the business environment even more...

https://www.pharmacompass.com/radio-compass-blog/drop-in-covid-sales-trial-failures-restructuring-trigger-steep-rise-in-layoffs-in-q1-2023

#PharmaFlow by PHARMACOMPASS
04 May 2023
Share Share

CDMO Activity Tracker: CDMOs expand operations in cell and gene therapies, biologics, HPAPIs

Excel Download
CDMO Activity Tracker: CDMOs expand operations in cell and gene therapies, biologics, HPAPIs
 

Impressions: 2162

The Covid-19 pandemic expedited the growth of contract development and manufacturing organizations (CDMOs) as pharma companies increasingly turned to them to accelerate drug development. However, by the end of 2022, a decline in demand for Covid ...

https://www.pharmacompass.com/radio-compass-blog/cdmos-expand-operations-in-cell-and-gene-therapies-biologics-hpapis

#PharmaFlow by PHARMACOMPASS
13 Apr 2023
Share Share

Company Tracker: Pfizer turns to acquisitions as Covid products’ sales nosedive

Excel Download
Company Tracker: Pfizer turns to acquisitions as Covid products’ sales nosedive
 

Impressions: 1917

Over the last five years, a lot has changed for Pfizer Inc, one of the world’s leading pharmaceutical companies based on pharma sales revenue. From entering into an agreement with German biotechnology company BioNTech SE in August 2018 fo...

https://www.pharmacompass.com/radio-compass-blog/company-tracker-pfizer-turns-to-acquisitions-as-covid-products-sales-nosedive

#PharmaFlow by PHARMACOMPASS
23 Mar 2023
Share Share

Endocrinology Newsmakers: Drugmakers work on triple agonist treatments, gene therapies to fight diabetes

Excel Download
Endocrinology Newsmakers: Drugmakers work on triple agonist treatments, gene therapies to fight diabetes
 

Impressions: 1626

Endocrinology, a medicinal branch that deals with endocrine and metabolic disorders, is witnessing cutting-edge drug research to develop advanced drugs that can treat diabetes, obesity, hypoparathyroidism and other disorders.The endocrinology mar...

https://www.pharmacompass.com/radio-compass-blog/endocrinology-newsmakers-drugmakers-work-on-triple-agonist-treatments-oral-insulin-to-fight-diabetes

#PharmaFlow by PHARMACOMPASS
02 Mar 2023
Share Share

Top 100 pharma & biotech deals in 2022

Excel Download
Top 100 pharma & biotech deals in 2022
 

Impressions: 2035

The pandemic years haven’t been great for dealmaking. Our analysis of top 10 biopharma M&A transactions shows that after a blockbuster 2019, when the combined value of top 10 biopharma M&A transactions had hit US$ 207 billion, M&A activity decr...

https://www.pharmacompass.com/radio-compass-blog/top-100-pharma-biotech-deals-in-2022

#PharmaFlow by PHARMACOMPASS
23 Feb 2023
Share Share

After cough syrup deaths, contaminated eye drops haunt Indian drug industry

Subscribe
After cough syrup deaths, contaminated eye drops haunt Indian drug industry
 

Impressions: 1148

India’s US$ 49 billion pharmaceutical industry has often been described as the ‘pharmacy to the world’, as it is the world’s largest exporter of generic drugs. But the country is having to contend with one scandal after a...

https://www.pharmacompass.com/radio-compass-blog/after-cough-syrup-deaths-contaminated-eye-drops-haunt-indian-drug-industry

#PharmaFlow by PHARMACOMPASS
09 Feb 2023
Share Share

DMF submissions rise 12.1% in 2022; India sees 10.6% drop in Type II filings

Excel Download
DMF submissions rise 12.1% in 2022; India sees 10.6% drop in Type II filings
 

Impressions: 1690

In 2022, the world finally began to emerge out of Covid-related restrictions. Though 2020 and 2021 saw several travel-related curbs, there was no let up in the speed at which generic active pharmaceutical ingredient (API) manufacturers were submit...

https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-rise-12-1-in-2022-india-sees-10-6-drop-in-type-ii-filings

#PharmaFlow by PHARMACOMPASS
02 Feb 2023
Share Share

Amgen ends Humira’s 20-year reign in US with Amjevita launch

Subscribe
Amgen ends Humira’s 20-year reign in US with Amjevita launch
 

Impressions: 1289

This week, AbbVie’s Humira (adalimumab) saw its 20-year exclusive run come to an end in the United States as Amgen launched its copycat — Amjevita. This is just the start of the onslaught of Humira copycats, as seven other biosimil...

https://www.pharmacompass.com/radio-compass-blog/amgen-ends-humira-s-20-year-reign-in-us-with-amjevita-launch

#PharmaFlow by PHARMACOMPASS
02 Feb 2023
Share Share

FDA’s drug approvals drop 26% due to Covid; okays three costly gene therapies in H2

Excel Download
FDA’s drug approvals drop 26% due to Covid; okays three costly gene therapies in H2
 

Impressions: 1812

The year 2022 saw the lowest number of drug approvals by the US Food and Drug Administration (FDA) since 2016. The agency’s Center for Drug Evaluation and Research (CDER) approved only 37 new drugs, a decrease of 26 percent from the 50 ...

https://www.pharmacompass.com/radio-compass-blog/fda-s-drug-approvals-drop-26-due-to-covid-okays-three-costly-gene-therapies-in-h2

#PharmaFlow by PHARMACOMPASS
19 Jan 2023
Share Share